AR056310A1 - Derivados de purina, procedimiento de obtencion, composiciones farmaceuticas y usos - Google Patents
Derivados de purina, procedimiento de obtencion, composiciones farmaceuticas y usosInfo
- Publication number
- AR056310A1 AR056310A1 ARP060101440A ARP060101440A AR056310A1 AR 056310 A1 AR056310 A1 AR 056310A1 AR P060101440 A ARP060101440 A AR P060101440A AR P060101440 A ARP060101440 A AR P060101440A AR 056310 A1 AR056310 A1 AR 056310A1
- Authority
- AR
- Argentina
- Prior art keywords
- atoms
- nhet
- hal
- mnr5r6
- ncyc
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Los compuestos de la formula I en donde X es OH o NH2, R1 es H o A, R2, R3 son en cada caso, de modo independiente entre sí, H, A, Hal, OH, OA o CN, R4 es Ar o Het1, R5, R6 son en cada caso, de modo independiente entre sí, H o A, A es fenilo, que no está sustituido o que puede estar mono-, di- o trisustituido con Hal, A, OA, OH, alquenilo con 2 a 6 átomos de C, alquinilo con 2 a 6 átomos de C, NO2, NR5R6, CONR5R6, COOH, COOA, CN, CHO, COA, fenilo, (CH2) nHet, O(CH2) nHet, NH(CH2) nHet, O(CH2)nCyc, NH(CH2)nCyc, O(CH2)mNR5R6, NR1(CH2)mNR5R6 y/u O(CH2)mNR1 (CH2)mOR1, Het1 es un heterociclo aromático mono- o bibíclico con 1 a 4 átomos de N, O Y/o S, que no está sustituido o que puede estar mono-, di- o trisustituido con Hal, A, OA, OH, alquenilo con 2 a 6 átomos de C, alquinilo con 2 a 6 átomos de C, NO2, NR5R6, CONR5R6, COOH, COOA, CN, CHO, COA, fenilo, (CH2)nHet, O(CH2)nHet, O(CH2)nCyc, NH(CH2)nCyc, O(CH2)mNR5r6, NR1(CH2)mNR5R6 y/u O(CH2)mNR1(CH2)mOR1, Het es un heterociclo mono- o bicíclico saturado, insaturado o aromático con 1 a 4 átomos de N, O y/o S, que puede no estar sustituido o que puede estar mono-, di- o trisustituido con Hal, A, OA, fenilo, COOA, CN y/u oxígeno del carbonilo (=O), A es alquilo con 1 a 10 átomos de C, en donde también 1-7 átomos de H pueden estar reemplazados por F y/o cloro, Cyc es cicloalquilo con 3 a 7 átomos de C, Hal es F, Cl, Br o I, n es 0, 1, 2, 3 o 4, m es 1, 2, 3 o 4, así como sus derivados, solvatos, sales, tautomeros y estereoisomeros de utilidad farmacéutica, incluyendo sus mezclas en todas las proporciones. Son inhibidores de las tirosina quinasas, en especial de la TIE-2, y de las Raf-quinasas, y pueden utilizarse, p.ej., para el tratamiento de tumores. Proceso de preparacion de dichos compuestos y composiciones farmacéuticas que los comprenden.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005017259A DE102005017259A1 (de) | 2005-04-14 | 2005-04-14 | Purinderivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056310A1 true AR056310A1 (es) | 2007-10-03 |
Family
ID=36579893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101440A AR056310A1 (es) | 2005-04-14 | 2006-04-12 | Derivados de purina, procedimiento de obtencion, composiciones farmaceuticas y usos |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20080214582A1 (es) |
| EP (1) | EP1869047A1 (es) |
| JP (1) | JP2008535874A (es) |
| AR (1) | AR056310A1 (es) |
| AU (1) | AU2006233530A1 (es) |
| CA (1) | CA2604294A1 (es) |
| DE (1) | DE102005017259A1 (es) |
| WO (1) | WO2006108482A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| JP6342805B2 (ja) * | 2011-09-02 | 2018-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途 |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| WO2016049774A1 (en) * | 2014-10-03 | 2016-04-07 | The Royal Institution For The Advancement Of Learning/Mcgill University | Urea and bis-urea based compounds and analogues thereof useful in the treatment of androgen receptor mediated diseases or disorders |
| US11471538B2 (en) | 2017-02-10 | 2022-10-18 | INSERM (Institut National de la Santéet de la Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway |
| JP7416716B2 (ja) | 2017-12-28 | 2024-01-17 | トラクト ファーマシューティカルズ インコーポレイテッド | 円柱上皮幹細胞のための幹細胞培養系およびそれに関連した使用法 |
| CN115710281B (zh) * | 2022-11-14 | 2024-05-17 | 南京中医药大学 | 一种异噁唑并[5,4-b]吡啶类FLT3抑制剂及其制备方法与用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005506350A (ja) * | 2001-10-18 | 2005-03-03 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン阻害薬としての１，４−二置換ベンゾ−縮合尿素化合物 |
| US20030199525A1 (en) * | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
| CA2535620A1 (en) * | 2003-08-15 | 2005-02-24 | Irm Llc | 6-substituted anilino purines as rtk inhibitors |
| TW200530236A (en) * | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
-
2005
- 2005-04-14 DE DE102005017259A patent/DE102005017259A1/de not_active Withdrawn
-
2006
- 2006-03-15 EP EP06723450A patent/EP1869047A1/de not_active Withdrawn
- 2006-03-15 AU AU2006233530A patent/AU2006233530A1/en not_active Abandoned
- 2006-03-15 JP JP2008505752A patent/JP2008535874A/ja active Pending
- 2006-03-15 US US11/910,776 patent/US20080214582A1/en not_active Abandoned
- 2006-03-15 CA CA002604294A patent/CA2604294A1/en not_active Abandoned
- 2006-03-15 WO PCT/EP2006/002380 patent/WO2006108482A1/de active Application Filing
- 2006-04-12 AR ARP060101440A patent/AR056310A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006108482A1 (de) | 2006-10-19 |
| JP2008535874A (ja) | 2008-09-04 |
| US20080214582A1 (en) | 2008-09-04 |
| CA2604294A1 (en) | 2006-10-19 |
| AU2006233530A1 (en) | 2006-10-19 |
| DE102005017259A1 (de) | 2006-10-19 |
| EP1869047A1 (de) | 2007-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056310A1 (es) | Derivados de purina, procedimiento de obtencion, composiciones farmaceuticas y usos | |
| AR051623A1 (es) | Derivados de piridopirimidinona | |
| AR056986A1 (es) | Aza heterociclos como inhibidores de quinasas. procedimiento de obtencion y composiciones farmaceuticas | |
| AR055772A1 (es) | Aza -heterociclos como inhibidores de quinasas, preparacion de los compuestos y medicamento preparado en base al compuesto | |
| AR074418A1 (es) | Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores | |
| PE20090964A1 (es) | Derivados de pirrolo[2,3-d]pirimidina como inhibidores de proteina quinasa b | |
| AR096235A1 (es) | Arilquinazolinas | |
| AR037972A1 (es) | Pirrolopirimidinas | |
| AR066543A1 (es) | Derivados de piridazinona | |
| AR078157A1 (es) | Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer | |
| AR046929A1 (es) | Piridopirimidinonas | |
| PE20070832A1 (es) | Derivados de piridazinona como inhibidores de la tirosina quinasa | |
| RS53673B1 (en) | FUNGICID MIXTURES CONTAINING SUBSTITUTED ANILIDES 1-METHYL-PIRAZOL-4-IL CARBOXYLIC ACIDS | |
| BR112014025564B8 (pt) | composto heterocíclico contendo nitrogênio ou sal do mesmo, composição farmacêutica e uso da mesma | |
| AR069843A1 (es) | Derivados de piridazinona, procedimiento para preparar dichos compuestos, composiciones farmaceuticas y usos de los mismos para preparar un medicamento | |
| AR051735A1 (es) | Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos. | |
| AR058205A1 (es) | 5-fenil-3,6-dihidro-2-oxo-6h-[1,3,4] tiadiazinas sustituidas | |
| DOP2014000055A (es) | Derivados de pirrolopirimidina y purina | |
| PE20161443A1 (es) | Compuestos | |
| AR060608A1 (es) | Inhibidores de la quinasa c- fms | |
| AR055376A1 (es) | Derivados de 1-acildihidropirazol | |
| AR072860A1 (es) | Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina | |
| AR066892A1 (es) | Derivados de benzoxazolona, proceso, medicamento, uso para tratar tumores y kit | |
| AR067081A1 (es) | Derivados de pirrolo[2,3-b]piridin-pirimidina,proceso de preparacion, medicamentos que los contienen y usos de los mismos para el tratamiento de tumores cancerigenos y metastasis tumorales. | |
| AR057899A1 (es) | Derivados de 3,6-dihidro-2-oxo-6h-[1,3,4]tiadiazina, metodo de preparacion, composiciones farmaceuticas que los contienen y usos en la terapia contra el cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |